Characteristics of recurrent in-stent restenosis after second- and third-generation drug-eluting stent implantation

被引:4
|
作者
Shimono, Hirokazu [1 ]
Kajiya, Takashi [1 ]
Takaoka, Junichiro [1 ]
Miyamura, Akihiro [1 ]
Inoue, Takafumi [1 ]
Kitazono, Kazunari [1 ]
Ninomiya, Toshiko [1 ]
Atsuchi, Yoshihiko [1 ]
Atsuchi, Nobuhiko [1 ]
Ohishi, Mitsuru [2 ]
机构
[1] Tenyoukai Cent Hosp, Dept Cardiol, Izumi Cho 6-7, Kagoshima 8920822, Japan
[2] Kagoshima Univ, Dept Cardiovasc Med & Hypertens, Kagoshima, Japan
关键词
drug-eluting stent; in-stent restenosis; optical coherence tomography; OPTICAL COHERENCE TOMOGRAPHY; EX-VIVO ASSESSMENT; OUTCOMES; NEOATHEROSCLEROSIS; PATTERNS;
D O I
10.1097/MCA.0000000000000945
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In second- and third-generation drug-eluting stent (DES) era, in-stent restenosis (ISR) is not commonly seen. However, a few patients still need repeat revascularizations for recurrent ISR even after second- and third-generation DES implantation. Methods From January 2012 to March 2017, 2339 lesions underwent second- and third-generation DES (Nobori, Promus Element, Resolute Integrity, Xience, Ultimaster and Synergy) implantation, of which 95 lesions (4.1%) underwent revascularization for first ISR. All lesions were divided into two groups of recurrent ISR group and non-recurrent ISR group. After successful optical coherence tomography (OCT) guided revascularization for all lesions, we investigated characteristics of recurrent ISR, and 2 years follow-up were completed. Results The mean age was 70.8 +/- 11.7 years, and 73.2% were males. Among 56 DES-ISR lesions which were assessed by OCT, recurrent ISR was seen in 33.9% (N = 19) at 2 years follow-up after revascularization for first ISR. Serum low-density lipoprotein-cholesterol (LDL-C) level was higher in recurrent ISR group compared with non-recurrent ISR group (114.1 +/- 53.9 mg/dl vs. 90.9 +/- 27.8 mg/dl, P = 0.04) and heterogeneous tissue pattern was more frequently found in recurrent ISR group compared with non-recurrent ISR group (63.2% vs. 27.0%, P = 0.03). Multivariate analysis identified a heterogeneous tissue pattern (odds ratio 3.71; 95% confidence interval 1.09-12.59; P = 0.03) as an independent predictor of recurrent restenosis. Conclusion Recurrent ISR of second- and third-generation DES was associated with heterogeneous tissue pattern of first ISR, and high LDL-C level was associated with recurrence.
引用
收藏
页码:36 / 41
页数:6
相关论文
共 50 条
  • [31] Prognostic Role of Fasting Remnant Cholesterol with In-Stent Restenosis After Drug-Eluting Stent Implantation
    Luo, Yinhua
    Cui, Shengyu
    Zhang, Changjiang
    Huang, Rui
    Zhao, Jinbo
    Su, Ke
    Luo, Dan
    Li, Yuanhong
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2022, 15 : 1733 - 1742
  • [32] Black hole restenosis after drug-eluting stent implantation for in-stent restenosis: potential mechanism and optimal strategy
    Otsuka, Yoritaka
    Murata, Takashi
    Kono, Michiaki
    Imoto, Hiroki
    Koyama, Taku
    Nakamura, Keita
    Kadama, Sunao
    Noguchi, Hiroo
    Saito, Taro
    HEART AND VESSELS, 2015, 30 (05) : 682 - 686
  • [33] Black hole restenosis after drug-eluting stent implantation for in-stent restenosis: potential mechanism and optimal strategy
    Yoritaka Otsuka
    Takashi Murata
    Michiaki Kono
    Hiroki Imoto
    Taku Koyama
    Keita Nakamura
    Sunao Kadama
    Hiroo Noguchi
    Taro Saito
    Heart and Vessels, 2015, 30 : 682 - 686
  • [34] Independent predictors of in-stent restenosis after drug-eluting stent implantation for ostial right coronary artery lesions
    Watanabe, Yusuke
    Takagi, Kensuke
    Naganuma, Toru
    Kawamoto, Hiroyoshi
    Fujino, Yusuke
    Ishiguro, Hisaaki
    Tahara, Satoko
    Kurita, Naoyuki
    Hosawa, Koji
    Nakamura, Shotaro
    Nakamura, Sunao
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 240 : 108 - 113
  • [35] From Mechanisms to Management: Tackling In-Stent Restenosis in the Drug-Eluting Stent Era
    Spadafora, Luigi
    Quarta, Rossella
    Martino, Giovanni
    Romano, Letizia
    Greco, Francesco
    Curcio, Antonio
    Gori, Tommaso
    Spaccarotella, Carmen
    Indolfi, Ciro
    Polimeni, Alberto
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [36] Outcomes of intravascular brachytherapy for recurrent drug-eluting in-stent restenosis
    Megaly, Michael
    Glogoza, Matthew
    Xenogiannis, Iosif
    Vemmou, Evangelia
    Nikolakopoulos, Ilias
    Willson, Laura
    Monyak, David J.
    Sullivan, Patsa
    Stanberry, Larissa
    Sorajja, Paul
    Chavez, Ivan
    Mooney, Michael
    Traverse, Jay
    Wang, Yale
    Garcia, Santiago
    Poulose, Anil
    Burke, Martin Nicholas
    Brilakis, Emmanouil S.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2021, 97 (01) : 32 - 38
  • [37] Random forest vs. logistic regression: Predicting angiographic in-stent restenosis after second-generation drug-eluting stent implantation
    Jiang, Zhi
    Tian, Longhai
    Liu, Wei
    Song, Bo
    Xue, Chao
    Li, Tianzong
    Chen, Jin
    Wei, Fang
    PLOS ONE, 2022, 17 (05):
  • [38] Comparison of in-stent neoatherosclerosis and tissue characteristics between early and late in-stent restenosis in second-generation drug-eluting stents: an optical coherence tomography study
    Sabbah, Mahmoud
    Kadota, Kazushige
    El-Eraky, Azza
    Kamal, Hanan M.
    Abdellah, Ahmed-Tageldien
    El Hawary, Ahmed
    INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2017, 33 (10) : 1463 - 1472
  • [39] Factors Associated with Coronary In-Stent Restenosis after Drug-Eluting Stent Implantation in Patients on Chronic Hemodialysis
    Sugita, Hiroshi
    Motohiro, Masayuki
    Morishita, Syun
    Tanaka, Masami
    Tsujimoto, Satoshi
    Shiojima, Ichiro
    BLOOD PURIFICATION, 2022, 51 (04) : 383 - 389
  • [40] Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis
    Zeng, MengYing
    Yan, XiaoWei
    Wu, Wei
    BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)